First renewable gasoline sample delivered to Audi
Global Bioenergies at a glance
Global Bioenergies has developed a process to convert plant-derived resources into a key family of ingredients used in the cosmetics industry. The process was first developed in a laboratory, where the Company is further enhancing performance.
It now operates as a pilot and a demo plant, with sufficient capacity to enable the Company to access the market by first creating a long-lasting makeup home brand.
The Company is gradually increasing its production capacities and is looking to improve the environmental footprint of not only the cosmetics industry but also that of other areas such as transportation and materials. Global Bioenergies is listed on Euronext Growth Paris (FR0011052257 – ALGBE)
Since 2008, Global Bioenergies has been
developing a process for transforming plant-based feedstocks
into cosmetic ingredients and aviation fuel.
Global Bioenergies in the news
Publication in Nature Communications of a paper describing the mechanism of enzymes yielding renewable isobutene
Global Bioenergies and Swift Fuel plan the first international flight of an aircraft powered by aviation gasoline made from over 97% renewable resources
Development in four stages
Proof of concept
To begin with, Global Bioenergies successfully set up a laboratory-scale prototype to provide proof of concept for its technology.
Secondly, after its IPO on the Alternext market, the Company refined its process on a laboratory scale.
Stage 3, which began when €23 million in funds were raised in mid-2013, was devoted to industrialization.
Joint-Venture avec Cristal Union
First isobutene delivery to Arkema
Prêt de 4,4M€ d’un consortium de banque française, démarrage de la construction du démonstrateur en Allemagne
Successful completion of the first isobutene test at its Pomacle-Bazancourt industrial pilot
Start-up of the industrial pilot
Partnership with Audi to develop a drop-in biofuel
€5.2 million in funding under the Investissements d’Avenir program
Partenariat avec ARKEMA et le CNRS
Synthos establishes a stake for €2.7 million